GROWTH STOCK ANALYZER Open the app
Growth Stock Analyzer › AMGN growth analysis
Growth stock analysis · updated 2026-07-27

Amgen Inc (AMGN) growth stock analysis

Is Amgen Inc a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.

Not right now by CANSLIM
49
Growth score
68
RS rating
#1,088
Rank
2/6
Traits passed
49/99
Growth score · 1088th of 4,897 US stocks
CANSLI
Six growth traits, scored 1–99

What the data says about AMGN

As of the 2026-07-27 close, AMGN scores 49 out of 99 on our growth-stock rating, a weak growth-stock profile. That ranks it 1088th of 4,897 rated US stocks, the top 22% of the market.

Its strongest trait is C (current quarterly earnings) at 83, and its weakest is S (supply & demand) at 30. AMGN clears 2 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.

On price, AMGN carries a middling Relative Strength rating of 68, meaning it has outperformed about 68% of the market over the past year.

Underneath the score: quarterly earnings up 4% year over year, sales up 6%, trading 3% below its 52-week high.

AMGN growth-trait breakdown

The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.

C
Current quarterly earnings
most recent EPS growth vs. a year ago
83
A
Annual earnings growth
multi-year earnings trend
47
N
New highs & catalysts
proximity to new 52-week highs
69
S
Supply & demand
volume behind the move vs. share supply
30
L
Leader or laggard
Relative Strength within its group
53
I
Institutional sponsorship
fund accumulation and 13F ownership
58

Is AMGN a growth stock?

Not right now by CANSLIM

On today’s data AMGN does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.

🔒 Stronger growth stocks than AMGN

The stocks ranking above AMGN today, the growth leaders you’d weigh against it.

See today’s top ranks for free →

🔒 AMGN price history & buy range

Where AMGN sits in its base, its 52-week path, and the trait trend over the past year.

Open the full AMGN profile →

See where AMGN ranks among every US growth stock

Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.

Open the app, free through September 1

AMGN as a growth stock, frequently asked

Is AMGN a good growth stock?

Not right now by CANSLIM. On today’s data AMGN does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.

What is AMGN's growth score?

Amgen Inc (AMGN) scores 49 out of 99 on our growth-stock rating as of the 2026-07-27 close, ranking 1088th of 4,897 rated US stocks.

Does AMGN have strong earnings growth?

AMGN's most recent quarterly earnings were up about 4% year over year, with sales up 6%.

How strong is AMGN's price performance?

AMGN has a Relative Strength rating of 68, meaning it has outperformed roughly 68% of the US market over the trailing year.

Where can I see AMGN's full analysis?

Create a free Growth Stock Analyzer account to see where AMGN ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.

Want the method behind the score? Read how we grade growth stocks with CANSLIM.

More growth stocks in Biological Products, (No Diagnostic Substances)